Skip to main content

AI-powered platform for autologous iPSC manufacturing

Objective

Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated disease and defective tissues, is unprecedented in history. However, the current methodologies prohibit standardized production of person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled. Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for autologous adoptive cancer immunotherapies, hematopoietic stem cell transplantation, and tissue regeneration.

The consortium will for the first time create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs fast and at a fraction of the current cost. Moreover, it will conduct cutting-edge single cell genomics and bioinformatics research of iPSC to identify clones of highest quality, and develop a database that will be the basis for AI software to select clones that meet clinical standards. The consortium comprises of experts in microfluidics engineering process automation for cell therapies, stem cell molecular biology and bioinformatics, GMP production, and AI modelling. The participating companies, startups, and universities are amongst the leading in Europe, and will promote the positions of female and early career participants from developed and developing European countries. The consortium aims to reach TRL3 prototype stage, and have created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine. Altogether, we propose to create revolutionary technology for low cost, fast, and standardized automated mass production of autologous iPSCs, which holds the potential to enable numerous new therapies and making them accessible to the public.

Coordinator

MIDA BIOTECH BV
Net EU contribution
€ 1 178 516,85
Address
Zernikedreef 9
2333 CK Leiden
Netherlands

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 178 516,85

Participants (3)

KVENTURES MONOPROSOPI I.K.E
Greece
Net EU contribution
€ 1 209 033,15
Address
Anastaseos 19
155 61 Athens

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 209 033,15
UNIVERSITEIT LEIDEN
Netherlands
Net EU contribution
€ 1 100 425,00
Address
Rapenburg 70
2311 EZ Leiden

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Other funding
€ 1 100 425,00
MIRCOD
Latvia
Net EU contribution
€ 511 250,00
Address
Matisa Iela 61a - 20
LV-2008 Riga

See on map

Region
Latvija Latvija Pierīga
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 511 250,00